InteRNA Technologies announced the establishment of its supervisory board, which will play a role in guiding the company to execute its business plan focused on the development of novel cancer therapies derived from miRNAs’.

The board is chaired by Anker Lundemose, MD, PhD, DMSc, a member of the boards of directors at both Topotarget and Adenium Biotech. Lundemose is a biotech entrepreneur and co-founder of several biotech companies, including Prosidion Ltd. and Symphogen.

Other members appointed include Mark Vaeck, PhD, chief executive officer of Complix, a biopharmaceutical company focused on the discovery and development of alphabodies. Previously, Vaeck was the founding chief executive officer of ActoGeniX, a biopharmaceutical company developing novel protein therapeutics for oral delivery and co-founder and chief executive officer of Ablynx, a biopharmaceutical company developing therapeutic antibody fragments. Sanne Weijzen, PhD, is a partner at Aglaia BioMedical Ventures, founding investor and majority shareholder in InteRNA Technologies through its Aglaia Oncology Seed Fund.

“We are pleased with the appointment of this international board of directors and feel honored to work together with an experienced team that is committed advising the company on its further transformation from a discovery oriented company to a product development company,” says Roel Schaapveld, chief executive officer of InteRNA Technologies.

Release Date: Nov. 21, 2011
Source: InteRNA Technologies